RBMX and non-Hodgkin lymphoma: Continuously, the multivariable analysis has been showing RBMX to be an independent prognostic marker for overall survival (p = 0.007; HR; 0.204; 95% CI: 0.064–0.646) and progression-free survival (p = 0.006; HR = 0.235; 95% CI: 0.083–0.666) in T-NHL.